The immunohistochemical analysis in the tumor tissues for the expression status of cell proliferation markers, PCNA and Ki67, and the apoptosis marker, cleaved PARP, revealed the augmented potency of Utt-B over sorafenib (Figure 2D). Here, PCNA is linked to neoplasm.